Navigation Links
U.S. Navy Requested Operations Trial on FDA Hold
Date:12/30/2008

CAMBRIDGE, Mass., Dec. 30 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that the Food and Drug Administration has advised the U.S. Naval Medical Research Center ("NMRC") by letter that it may not initiate a clinical trial of Biopure's product Hemopure [hemoglobin glutamer - 250 (bovine)], under a proposed protocol submitted to the FDA on November 21, 2008. As previously announced, the Navy had filed a protocol for a proposed trial for the resuscitation of operational casualties with severe hemorrhagic shock without availability of blood transfusions ("Op RESUS").

While the FDA letter acknowledges that the proposed trial addresses some of FDA's concerns previously communicated, it gives three regulatory bases for the hold: safety of subjects, protocol design deficient to meet its stated objectives; and the content of the investigator brochure (a summary of information for those carrying out the trial) and related items. Concerning safety, the FDA hold letter refers to the risk of exacerbation of bleeding resulting from product infusion and the "adverse event profile of [Hemopure]." However, the letter refers in particular to the results of three previous trauma trials with adverse mortality rates, none of which was a Hemopure trial and one of which, according to the FDA, did not involve a hemoglobin based oxygen carrier. According to the FDA, based on these trials with other products, it cannot presently approve IND protocols with agents that may raise blood pressure in acute hemorrhagic shock.

The letter requests a "Clinical Hold Complete Response." The Company does not know how the NMRC will proceed.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. On November 21, 2008, the Company announced that it had terminated most of its work force for financial reasons. Using its limited resources, the Company is developing Hemopure and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold more than 200,000 units of Oxyglobin since its launch.

Statements in this release that are not strictly historical are forward-looking statements, including any statements implying that the Company or the U.S. Navy will be able to proceed with any clinical trial of Hemopure. Actual results and their timing may differ materially from those projected in these forward-looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the company's financial position, including its limited cash resources and need to raise additional capital to pursue its business, delays and adverse determinations by the FDA and other regulatory authorities, unanticipated problems with the product's commercial use, whether or not product related, delays in clinical trials, and the other factors identified under the heading "Risk Factors" in the Company's quarterly report on Form 10-Q filed on September 15, 2008, which can be accessed in the EDGAR database at the U.S. Securities and Exchange Commission's (SEC) website, http://www.sec.gov. The company undertakes no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. A full discussion of the company's operations and financial condition can be found in the company's filings with the SEC.

    Contact:  Rob Skiba
              Biopure Corporation
              (617) 234-6500
              IR@biopure.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. $3 Million Requested by UNFPA to Help Women and Girls Displaced by Myanmar Cyclone
2. Danialle Karmanos Work It Out Names Tracey Secco as Director of Operations
3. PRA International Expands Operations in Mexico
4. DNA2.0 Expands European Presence By Opening UK Office: Experienced Life Sciences Executive, Dr. Michael Dyson, to Lead European Operations
5. Duane Reade Holdings, Inc. Further Strengthens Management Team With Addition of Frank Scorpiniti, SVP, Pharmacy Operations
6. Operations engineering for more efficient operating rooms
7. Frost & Sullivan Lauds StatCom for Its Hospital Operations System
8. Warriors Unite: Mike Ditka & the Gridiron Greats Form Partnership to Assist Retired NFL Players & U.S. Military Special Operations Personnel
9. Jonathan Jacobson Appointed General Manager, Global Business Strategies & Operations, Menicon Co., Ltd.
10. AmeriCares Launches India Operations
11. Accumetrics, Inc. Appoints William Dippel as Executive Vice President of Operations and R&D
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... If you are thinking of a visit to San Francisco ... October is the perfect time to visit. , Business Architecture Associates is pleased to offer ... for individuals, as a 4-½ day package for individuals, and as 4-½ day corporate package ...
(Date:5/24/2017)... ... May 24, 2017 , ... Technique, technique, technique – with a ... lifting weights for strength training and exercise or simply lifting heavy objects, advises Dr. ... position is everything,” Dr. Chang says. “Improper technique in lifting anything heavy or an ...
(Date:5/23/2017)... ... 23, 2017 , ... PM360, the premier information resource for ... winners of its 3rd Annual ELITE Awards. The ELITE (Exceptional • Leaders • ... industry today. , Out of more than 500 submissions, 100 winners were selected ...
(Date:5/23/2017)... ... May 23, 2017 , ... London, May 23, 2017: ... serve earlier this month as a Guest Speaker and Contributor to a weeklong series ... and Common Purpose. , Walter Schindler and SAIL Capital ...
(Date:5/23/2017)... IN (PRWEB) , ... May 23, 2017 , ... ... the availability of video chat as a standard feature on its secure clinical ... from text to voice to video depending on the type and urgency of ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... 10, 2017 CSSi, the global leader in ... research industry, is proud to announce the launch of ... website features both enriched content and a customized layout ... the company,s already well-established position as the top global ... "After many months of hard work, we are delighted ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals ... ), a clinical-stage pharmaceutical company focused on the ... that the Canadian Intellectual Property Office has granted ... Oral Administration of Exenatide". The patent covers Oramed,s ... GLP-1 is an incretin hormone that ...
(Date:5/8/2017)... FLINT, Mich. , May 8, 2017  Diplomat ... WRB Communications, Inc. ("WRB"), a health care ... . WRB specializes in relationship management ... organizations. WRB will ... of Diplomat,s commercialization support services for manufacturers, biotech firms, ...
Breaking Medicine Technology: